PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.24 CNY 2.23% Market Closed
Market Cap: 7B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PharmaBlock Sciences Nanjing Inc
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Cash Paid for Dividends
-ÂĄ81.2m
CAGR 3-Years
-61%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash Paid for Dividends
-ÂĄ652.1m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash Paid for Dividends
-ÂĄ2.2B
CAGR 3-Years
-57%
CAGR 5-Years
-41%
CAGR 10-Years
-28%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash Paid for Dividends
-ÂĄ1.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-26%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash Paid for Dividends
-ÂĄ3.7B
CAGR 3-Years
9%
CAGR 5-Years
-10%
CAGR 10-Years
-22%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash Paid for Dividends
-ÂĄ18.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
53.37 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Cash Paid for Dividends?
Cash Paid for Dividends
-81.2m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Cash Paid for Dividends amounts to -81.2m CNY.

What is PharmaBlock Sciences Nanjing Inc's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 5Y
-25%

Over the last year, the Cash Paid for Dividends growth was -105%. The average annual Cash Paid for Dividends growth rates for PharmaBlock Sciences Nanjing Inc have been -61% over the past three years , -25% over the past five years .

Back to Top